Latest available resultsQuarter ended June 30, 202610-Q · July 30, 2026
Filed with the SECREGENERON PHARMACEUTICALS, INC.
REGNPharma & biotech
Next reportOctober 26, 2026Analyst forecast 16.171 $/share
Revenue
$4.29B
▲ +16.7% vs prior year% YoY
Net income
$1.30B
▼ -6.8% vs prior year% YoY
EPS
12.23$
▼ -4.5% vs prior year% YoY
Net margin
30.2%
▼ -7.6 percentage points vs prior year pp YoY
Revenue▲ +16.7 %
Margins (% of revenue)Gross N/AOperatingNet
Net income▼ -6.8 %
EPS▼ -4.5 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $4.29B | |
| Gross profit | — | |
| Operating income | $1.29B | 30.1 % |
| Net income | $1.30B | 30.2 % |
| R&D | $1.63B | 38.0 % |
| EPS (diluted) | 12.23 $ | |
| Balance sheet | ||
| Assets | $41.73B | |
| Liabilities | $10.02B | |
| Equity | $31.71B | |
| Cash | $2.46B | |
| Capital | ||
| Shares outstanding | — | |
| Public float | — | |